BAIRD MEDICAL INVESTMENT HOL (BDMD) Fundamental Analysis & Valuation

NASDAQ:BDMD • KYG0705H1039

Current stock price

2.4 USD
+0.19 (+8.6%)
At close:
2.3998 USD
0 (-0.01%)
After Hours:

This BDMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. BDMD Profitability Analysis

1.1 Basic Checks

  • In the past year BDMD was profitable.
  • BDMD had a negative operating cash flow in the past year.
  • In multiple years BDMD reported negative net income over the last 5 years.
  • BDMD had a negative operating cash flow in each of the past 5 years.
BDMD Yearly Net Income VS EBIT VS OCF VS FCFBDMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

1.2 Ratios

  • BDMD has a better Return On Assets (16.24%) than 95.65% of its industry peers.
  • Looking at the Return On Equity, with a value of 35.14%, BDMD belongs to the top of the industry, outperforming 98.37% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 24.25%, BDMD belongs to the top of the industry, outperforming 98.37% of the companies in the same industry.
Industry RankSector Rank
ROA 16.24%
ROE 35.14%
ROIC 24.25%
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDMD Yearly ROA, ROE, ROICBDMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

  • BDMD's Profit Margin of 33.76% is amongst the best of the industry. BDMD outperforms 99.46% of its industry peers.
  • Looking at the Operating Margin, with a value of 41.35%, BDMD belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • BDMD's Gross Margin of 88.17% is amongst the best of the industry. BDMD outperforms 97.28% of its industry peers.
Industry RankSector Rank
OM 41.35%
PM (TTM) 33.76%
GM 88.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDMD Yearly Profit, Operating, Gross MarginsBDMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BDMD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BDMD is creating value.
  • The number of shares outstanding for BDMD has been reduced compared to 1 year ago.
  • BDMD has a worse debt/assets ratio than last year.
BDMD Yearly Shares OutstandingBDMD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
BDMD Yearly Total Debt VS Total AssetsBDMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 3.07 indicates that BDMD is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.07, BDMD is doing good in the industry, outperforming 69.57% of the companies in the same industry.
  • A Debt/Equity ratio of 0.56 indicates that BDMD is somewhat dependend on debt financing.
  • BDMD has a Debt to Equity ratio of 0.56. This is comparable to the rest of the industry: BDMD outperforms 40.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z 3.07
ROIC/WACC2.83
WACC8.56%
BDMD Yearly LT Debt VS Equity VS FCFBDMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 1.71 indicates that BDMD should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.71, BDMD is doing worse than 69.02% of the companies in the same industry.
  • A Quick Ratio of 1.67 indicates that BDMD should not have too much problems paying its short term obligations.
  • BDMD's Quick ratio of 1.67 is in line compared to the rest of the industry. BDMD outperforms 44.02% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.67
BDMD Yearly Current Assets VS Current LiabilitesBDMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BDMD Growth Analysis

3.1 Past

  • BDMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.58%, which is quite good.
  • Looking at the last year, BDMD shows a quite strong growth in Revenue. The Revenue has grown by 17.74% in the last year.
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-356.32%
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.41%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDMD Yearly Revenue VS EstimatesBDMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 10M 20M 30M

More info and screens

Find the best growth stocksShow best growing peers

3

4. BDMD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.00, the valuation of BDMD can be described as very cheap.
  • Based on the Price/Earnings ratio, BDMD is valued cheaply inside the industry as 97.83% of the companies are valued more expensively.
  • BDMD is valuated cheaply when we compare the Price/Earnings ratio to 25.70, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5
Fwd PE N/A
BDMD Price Earnings VS Forward Price EarningsBDMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BDMD is valued cheaply inside the industry as 98.37% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5.31
BDMD Per share dataBDMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BDMD Dividend Analysis

5.1 Amount

  • BDMD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BDMD Fundamentals: All Metrics, Ratios and Statistics

BAIRD MEDICAL INVESTMENT HOL

NASDAQ:BDMD (3/13/2026, 8:11:17 PM)

After market: 2.3998 0 (-0.01%)

2.4

+0.19 (+8.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-15
Earnings (Next)N/A
Inst Owners1.44%
Inst Owner ChangeN/A
Ins Owners49.82%
Ins Owner ChangeN/A
Market Cap88.15M
Revenue(TTM)37.04M
Net Income(TTM)12.50M
AnalystsN/A
Price TargetN/A
Short Float %0.42%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 5
Fwd PE N/A
P/S 2.38
P/FCF N/A
P/OCF N/A
P/B 2.48
P/tB 2.48
EV/EBITDA 5.31
EPS(TTM)0.48
EY20%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.01
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.23
Profitability
Industry RankSector Rank
ROA 16.24%
ROE 35.14%
ROCE 36.88%
ROIC 24.25%
ROICexc 25.24%
ROICexgc 25.27%
OM 41.35%
PM (TTM) 33.76%
GM 88.17%
FCFM N/A
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA 1.2
Cap/Depr 210.97%
Cap/Sales 6.52%
Interest Coverage 24.84
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.67
Altman-Z 3.07
F-Score2
WACC8.56%
ROIC/WACC2.83
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-356.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-249.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.28%
OCF growth 3YN/A
OCF growth 5YN/A

BAIRD MEDICAL INVESTMENT HOL / BDMD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BDMD.


What is the valuation status of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?

ChartMill assigns a valuation rating of 3 / 10 to BAIRD MEDICAL INVESTMENT HOL (BDMD). This can be considered as Overvalued.


How profitable is BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?

BAIRD MEDICAL INVESTMENT HOL (BDMD) has a profitability rating of 5 / 10.


What is the valuation of BAIRD MEDICAL INVESTMENT HOL based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BAIRD MEDICAL INVESTMENT HOL (BDMD) is 5 and the Price/Book (PB) ratio is 2.48.